Journal of Oncology Translational Research

ISSN: 2476-2261

Open Access

Advances in ALK Targeted Therapy for Neuroblastoma


Libo Zhang and Sylvain Baruchel

Significant advances have been made to understand the association between ALK genetic aberrations and disease prognosis in neuroblastoma. ALK targeted therapies are evolving quickly and several randomized controlled trials of ALK inhibitors are underway or nearing completion in adult cancers. Ongoing research will bring new challenges and newer technologies to fully define the pathogenic and prognostic alterations, to stratify the risk of recurrence or progression, and to develop optimal monitoring and treatment strategies in this malignancy.


Share this article

arrow_upward arrow_upward